Fingerprint
Dive into the research topics of 'Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically